<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inhaled beta agonist doses used for initial management of asthma exacerbations in children &lt;12 years of age*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inhaled beta agonist doses used for initial management of asthma exacerbations in children &lt;12 years of age*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Inhaled beta agonist doses used for initial management of asthma exacerbations in children &lt;12 years of age*</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="11%"></colgroup><colgroup span="3" width="26%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Dose form</td> <td class="subtitle1">0 to &lt;4 years</td> <td class="subtitle1">4 to 11 years</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Metered dose inhaler (MDI)</td> </tr> <tr> <td class="indent1">Albuterol (salbutamol) HFA MDI with spacer (valved holding chamber)</td> <td> <ul> <li>90 mcg/puff</li> </ul> </td> <td> <ul> <li>Home management – 2 to 4 inhalations, can be repeated every 20 minutes for a total of 3 doses, then up to every 4 hours as directed<sup>¶</sup></li> <li>Acute care setting – 4 to 8 inhalations every 20 minutes for 3 doses<sup>Δ</sup>, then up to every 1 hour as needed</li> </ul> </td> <td> <ul> <li>Home management – 2 to 4 inhalations, can be repeated every 20 minutes for a total of 3 doses, then up to every 4 hours as directed<sup>¶</sup></li> <li>Acute care setting – 4 to 8 inhalations every 20 minutes for 3 doses<sup>Δ</sup>, then up to every 1 hour as needed</li> </ul> </td> <td rowspan="2"> <ul> <li>Differences in potencies exist, but products shown are essentially comparable on a per-puff basis.</li> <li>An increasing use or lack of expected effect indicates diminished control of asthma.</li> <li>Not recommended for long-term daily treatment. Regular use exceeding 2 days/week for symptom control (not prevention of EIB) indicates the need for additional long-term control therapy.</li> <li>Periodically clean mouthpiece as drug may plug orifice.</li> <li>Instructions for use, priming, and cleaning MDI vary by brand. For specific information, refer to UpToDate topic on use of inhaler devices in children, Lexicomp, and patient leaflet included with MDI.</li> </ul> </td> </tr> <tr> <td class="indent1">Levalbuterol (levosalbutamol) HFA MDI with spacer (valved holding chamber)</td> <td> <ul> <li>45 mcg/puff</li> </ul> </td> <td> <ul> <li>Safety and efficacy not established in children &lt;4 years</li> </ul> </td> <td> <ul> <li>Home management – 2 to 4 inhalations, can be repeated every 20 minutes for a total of 3 doses, then up to every 4 hours as directed<sup>¶</sup></li> <li>Acute care setting – 4 to 8 inhalations every 20 minutes for 3 doses<sup>Δ</sup>, then up to every 1 hour as needed</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Dry powder inhaler (DPI)</td> </tr> <tr> <td class="indent1">Albuterol (salbutamol) breath-activated DPI</td> <td> <ul> <li>90 mcg/inhalation</li> </ul> </td> <td> <ul> <li>Safety and efficacy not established in children &lt;4 years</li> </ul> </td> <td> <ul> <li>Home management – 2 to 4 inhalations, can be repeated every 20 minutes for a total of 3 doses, then up to every 4 hours as directed<sup>¶</sup></li> </ul> </td> <td> <ul> <li>DPI alternative for prophylactic use prior to exercise in older children who are comfortable with and capable of properly using a breath-activated inhaler technique.</li> <li>Use of DPI is not advised as rescue therapy in an acute setting, as some children may be unable to generate sufficient inspiratory flow rate to assure optimal lung deposition of drug.</li> <li><strong>NOTE:</strong> DPIs can contain lactose and trace milk proteins (ie, potential allergens).</li> <li>Also refer to information above on albuterol MDI.</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Nebulizer solution</td> </tr> <tr> <td class="indent1">Albuterol (salbutamol)</td> <td> <ul> <li>0.63 mg/3 mL</li> <li>1.25 mg/3 mL</li> <li>2.5 mg/3 mL</li> <li>5 mg/mL (0.5%)</li> </ul> </td> <td> <ul> <li>Home management – 1.25 to 2.5 mg, can be repeated every 20 minutes for a total of 3 doses, then up to every 4 hours as directed<sup>¶</sup></li> <li>Acute care setting – 0.15 mg/kg per dose (minimum 2.5 mg, maximum 5 mg/dose) up to every 20 minutes for up to 3 doses, then 0.15 to 0.3 mg/kg (maximum 10 mg) up to every 30 minutes as needed or switch to continuous therapy if in a critical care setting</li> <li> <p>Critical care setting and severe exacerbation – Continuous nebulizer treatment 0.5 mg/kg per hour (maximum 20 mg per hour) by large-volume nebulizer.</p> Dose may also be determined based upon body weight as follows: <ul> <li>5 to 10 kg – 5 to 7.5 mg per hour</li> <li>10 to 20 kg – 10 to 12.5 mg per hour</li> <li>&gt;20 kg – 15 to 20 mg per hour</li> </ul> </li> </ul> </td> <td> <ul> <li>Home management – 2.5 to 5 mg, can be repeated every 20 minutes for a total of 3 doses, then up to every 4 hours as directed<sup>¶</sup></li> <li>Acute care setting – 0.15 mg/kg per dose (minimum 2.5 mg, maximum 5 mg/dose) up to every 20 minutes for up to 3 doses, then 0.15 to 0.3 mg/kg (maximum 10 mg) every 30 minutes to 4 hours as needed or switch to continuous therapy if in a critical care setting</li> <li>Critical care setting and severe exacerbation – Continuous nebulizer treatment 0.5 mg/kg per hour (maximum 20 mg per hour) by large-volume nebulizer; weight-based dosing is also an option (refer to 0 to &lt;4 years)</li> </ul> </td> <td> <ul> <li>May mix with budesonide suspension, ipratropium solution, or cromolyn sodium solution for nebulization.</li> </ul> </td> </tr> <tr> <td class="indent1">Levalbuterol (levosalbutamol)</td> <td> <ul> <li>0.31 mg/3 mL</li> <li>0.63 mg/3 mL</li> <li>1.25 mg/0.5 mL</li> <li>1.25 mg/3 mL</li> </ul> </td> <td> <ul> <li>Home management – 0.63 to 1.25 mg, can be repeated every 20 minutes for a total of 3 doses, then up to every 4 hours as directed<sup>¶</sup></li> <li>Acute care setting – 0.75 mg/kg per dose (minimum 1.25 mg, maximum 2.5 mg/dose) up to every 20 minutes for up to 3 doses, then 0.075 to 0.15 mg/kg (maximum 5 mg) up to every 30 minutes as needed</li> <li>Critical care setting and severe exacerbation – Continuous nebulizer treatment 0.25 mg/kg per hour (maximum 10 mg per hour) by large-volume nebulizer</li> </ul> </td> <td> <ul> <li>Home management – 0.63 to 1.25 mg, can be repeated every 20 minutes for a total of 3 doses, then up to every 4 hours as directed<sup>¶</sup></li> <li>Acute care setting – 0.75 mg/kg per dose (minimum 1.25 mg, maximum 2.5 mg/dose) up to every 20 minutes for up to 3 doses, then 0.075 to 0.15 mg/kg (maximum 5 mg) up to every 30 minutes as needed</li> <li>Critical care setting and severe exacerbation – Continuous nebulizer treatment 0.25 mg/kg per hour (maximum 10 mg per hour) by large-volume nebulizer</li> </ul> </td> <td> <ul> <li>May mix with budesonide suspension, ipratropium solution, or cromolyn sodium solution for nebulization.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Also refer to separate UpToDate topic reviews and table on recommended doses of medications other than inhaled beta agonists to treat children with an acute asthma exacerbation.</li>
<li>Nonselective inhaled agents (ie, epinephrine, isoproterenol, metaproterenol) and orally administered beta<sub>2</sub>-agonists are not recommended, due to their potential for excessive cardiac stimulation, especially in high doses. For severely ill children, however, IM or SC epinephrine may be administered for rapid relief.</li>
</ul></div><div class="graphic_footnotes">HFA: hydrofluoroalkane; 
	EIB: exercise-induced bronchoconstriction; 
	IM: intramuscular; 
	SC: subcutaneous.<br/>
	
	* Doses are provided for those products that have been approved by the US Food and Drug Administration or have sufficient clinical trial safety and efficacy data in the appropriate age ranges to support their use. Doses shown and strengths (ie, mcg per puff or inhalation) are based upon product descriptions approved in the United States, which may differ from how strengths are described for products available in other countries. Consult local product information before use.<br/>
	
	¶ Typically, 2 puffs are used for mild-to-moderate symptoms and 4 puffs for more severe symptoms and/or for patients who are older and/or weigh more. Children (excluding infants) with more severe symptoms may require up to 6 inhalations per dose. Over the course of these 3 short-acting beta agonist treatments, the caregiver can determine (based on action plan or clinician guidance) whether to continue care at home or seek additional medical attention.<br/>
	
	Δ The number of inhalations is based up on the severity of respiratory impairment, age and weight of the patient, number of inhalations the patient has already received, and availability of monitoring. When administering an albuterol MDI for acute asthma exacerbation, use of a valved holding chamber (with a mask in children &lt;4 years of age) and careful attention to technique are recommended.</div><div class="graphic_reference">Data from:
	<ol>
<li>National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</li>
<li>2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. <a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines" target="_blank">https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines</a> (Accessed on October 18, 2021).</li>
<li>Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, updated 2021. <a href="https://ginasthma.org/reports/" target="_blank">https://ginasthma.org/reports/</a> (Accessed on October 18, 2021).</li>
<li>Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
</ol></div><div id="graphicVersion">Graphic 134102 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
